Location Directory

Clinical trials in Baltimore, Maryland

This page shows live ClinicalTrials.gov search results for Baltimore, Maryland, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

13749

Shown on this page

Current sort

Institutions in Baltimore

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Johns Hopkins

Live official records

Open in full search

Conditions: Trauma, Hemorrhage
Interventions: Calcium Gluconate, Vasopressin, saline placebo; Drug
Lead sponsor: Jason Sperry; Other
Eligibility: 18 Years to 90 Years
Enrollment: 1,050 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 18
States / cities: Chandler, Arizona • Tucson, Arizona • Little Rock, Arkansas + 13 more

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: mezigdomide, Pomalidomide, Bortezomib, Dexamethasone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 810 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 56
States / cities: Los Alamitos, California • San Diego, California • West Hollywood, California + 50 more

Conditions: Opioid Use Disorder
Interventions: Mobile phone-assisted intervention, Peer navigator, Standard of care referral for out-patient MAT; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: ZEN-3694, Testosterone cypionate, Enzalutamide, Luteinizing hormone-releasing hormone (LHRH) analogue; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV, Violence, Gender-Based, Pre-Exposure Prophylaxis
Interventions: Individual PrEP Decision Aid, CDC PrEP Video, Shared PrEP Decision Aid; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lupus Erythematosus, Systemic
Interventions: Cenerimod, Placebo; Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 22
States / cities: Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more

Conditions: Serious Illness, Palliative
Interventions: Palliative care needs information, Default consult order; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 18,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Clinton, Maryland + 2 more

Conditions: CRC (Colorectal Cancer)
Interventions: INCA33890, Placebo, Bevacizumab, FOLFOX; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 78
States / cities: Mobile, Alabama • Tucson, Arizona • Fountain Valley, California + 65 more

Conditions: Transplant;Failure,Kidney, Transplant; Failure, Liver, Adherence, Medication, Adherence, Patient, Adherence, Treatment
Interventions: mHealth Messaging Intervention Group; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 13 Years to 25 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
Interventions: NEU-411, Placebo; Drug · Other
Lead sponsor: Neuron23 Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 45
States / cities: Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 40 more

Conditions: Anxiety Symptoms, Post-traumatic Stress Symptoms, Depressive Symptoms, Behavioral Problems
Interventions: RAP Club Delivered by a School Clinician, RAP Club Delivered by a Teacher, Standard Supervision, Enhanced Supervision; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 12 Years to 15 Years
Enrollment: 960 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: Baltimore, Maryland

Conditions: Neuropathic Pain, Chronic Pain
Interventions: Scrambler Therapy MC-5A Device; Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 5 Years to 26 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Clinical trials in Baltimore, Maryland

Filter and sort this location

Institutions in Baltimore

Live official records

CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Peer-led, Mobile App Supported Linkage to Opioid Use Disorder Treatment

The COSMYC Trial (COmbined Suppression of MYC)

Development and Evaluation of a PrEP Decision Aid for Women Seeking Domestic Violence Services in Baltimore

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Nudging Effective and Equitable Delivery of Specialty Palliative Care

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

Improving Student Mental Health Through a Universal Trauma-Informed Intervention

Pediatric Electrocutaneous Analgesia for Children Experiencing Neuropathic Pain